MINNEAPOLIS , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously

MINNEAPOLIS , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into

MINNEAPOLIS , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously

MINNEAPOLIS , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into

EAGAN, Minn. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc.

MINNEAPOLIS , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously

MINNEAPOLIS , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into

Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic MINNEAPOLIS , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial

MINNEAPOLIS , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations

Reincorporation Proposal Received Overwhelming Support Among Shares Voted NEW YORK , Dec. 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today